Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Aptevo Therapeutics (APVO) Cost of Revenue (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Cost of Revenue for 5 consecutive years, with $6.1 million as the latest value for Q4 2019.

  • Quarterly Cost of Revenue changed N/A to $6.1 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $19.9 million through Dec 2019, changed N/A year-over-year, with the annual reading at $19.9 million for FY2019, 77.7% up from the prior year.
  • Cost of Revenue hit $6.1 million in Q4 2019 for Aptevo Therapeutics, up from $4.0 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $6.5 million in Q2 2016 to a low of $488000.0 in Q1 2017.
  • Historically, Cost of Revenue has averaged $3.8 million across 5 years, with a median of $3.9 million in 2019.
  • Biggest five-year swings in Cost of Revenue: tumbled 86.17% in 2017 and later skyrocketed 264.96% in 2018.
  • Year by year, Cost of Revenue stood at $5.2 million in 2015, then dropped by 3.0% to $5.1 million in 2016, then plummeted by 62.68% to $1.9 million in 2017, then increased by 28.53% to $2.4 million in 2018, then soared by 151.78% to $6.1 million in 2019.
  • Business Quant data shows Cost of Revenue for APVO at $6.1 million in Q4 2019, $4.0 million in Q3 2019, and $6.0 million in Q2 2019.